TISIDB

Summary
Symbol	PIK3R5
Name	phosphoinositide-3-kinase, regulatory subunit 5
Aliases	P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Cytoplasm Cell membrane Peripheral membrane protein Note=Predominantly localized in the nucleus in absence of PIK3CG/p120. Colocalizes with PIK3CG/p120 in the cytoplasm. Translocated to the plasma membrane in a beta-gamma G protein-dependent manner.
Domain	PF10486 Phosphoinositide 3-kinase gamma adapter protein p101 subunit
Function	Regulatory subunit of the PI3K gamma complex. Required for recruitment of the catalytic subunit to the plasma membrane via interaction with beta-gamma G protein dimers. Required for G protein-mediated activation of PIK3CG (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0006644 phospholipid metabolic process GO:0006650 glycerophospholipid metabolic process GO:0006661 phosphatidylinositol biosynthetic process GO:0007596 blood coagulation GO:0007599 hemostasis GO:0008654 phospholipid biosynthetic process GO:0014065 phosphatidylinositol 3-kinase signaling GO:0019216 regulation of lipid metabolic process GO:0030168 platelet activation GO:0030258 lipid modification GO:0033674 positive regulation of kinase activity GO:0043405 regulation of MAP kinase activity GO:0043406 positive regulation of MAP kinase activity GO:0043410 positive regulation of MAPK cascade GO:0043491 protein kinase B signaling GO:0043550 regulation of lipid kinase activity GO:0043551 regulation of phosphatidylinositol 3-kinase activity GO:0045017 glycerolipid biosynthetic process GO:0045860 positive regulation of protein kinase activity GO:0046474 glycerophospholipid biosynthetic process GO:0046486 glycerolipid metabolic process GO:0046488 phosphatidylinositol metabolic process GO:0046834 lipid phosphorylation GO:0046854 phosphatidylinositol phosphorylation GO:0048015 phosphatidylinositol-mediated signaling GO:0048017 inositol lipid-mediated signaling GO:0050817 coagulation GO:0050878 regulation of body fluid levels GO:0051896 regulation of protein kinase B signaling GO:0051897 positive regulation of protein kinase B signaling GO:0071900 regulation of protein serine/threonine kinase activity GO:0071902 positive regulation of protein serine/threonine kinase activity GO:1903725 regulation of phospholipid metabolic process
Molecular Function	GO:0019207 kinase regulator activity GO:0031683 G-protein beta/gamma-subunit complex binding GO:0035004 phosphatidylinositol 3-kinase activity GO:0035014 phosphatidylinositol 3-kinase regulator activity GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046935 1-phosphatidylinositol-3-kinase regulator activity GO:0052813 phosphatidylinositol bisphosphate kinase activity
Cellular Component	GO:0005942 phosphatidylinositol 3-kinase complex GO:0005944 phosphatidylinositol 3-kinase complex, class IB GO:0019898 extrinsic component of membrane GO:0061695 transferase complex, transferring phosphorus-containing groups GO:0097651 phosphatidylinositol 3-kinase complex, class I

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04022 cGMP-PKG signaling pathway hsa04151 PI3K-Akt signaling pathway hsa04261 Adrenergic signaling in cardiomyocytes hsa04611 Platelet activation hsa04725 Cholinergic synapse hsa04921 Oxytocin signaling pathway
Reactome	R-HSA-392451: G beta R-HSA-397795: G-protein beta R-HSA-388396: GPCR downstream signaling R-HSA-114604: GPVI-mediated activation cascade R-HSA-109582: Hemostasis R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-1483255: PI Metabolism R-HSA-1483257: Phospholipid metabolism R-HSA-76002: Platelet activation, signaling and aggregation R-HSA-162582: Signal Transduction R-HSA-372790: Signaling by GPCR R-HSA-1660499: Synthesis of PIPs at the plasma membrane

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04022 cGMP-PKG signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04261 Adrenergic signaling in cardiomyocytes
hsa04611 Platelet activation
hsa04725 Cholinergic synapse
hsa04921 Oxytocin signaling pathway

Reactome

R-HSA-392451: G beta
R-HSA-397795: G-protein beta
R-HSA-388396: GPCR downstream signaling
R-HSA-114604: GPVI-mediated activation cascade
R-HSA-109582: Hemostasis
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1483255: PI Metabolism
R-HSA-1483257: Phospholipid metabolism
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-1660499: Synthesis of PIPs at the plasma membrane

Summary
Symbol	PIK3R5
Name	phosphoinositide-3-kinase, regulatory subunit 5
Aliases	P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PIK3R5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between PIK3R5 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
21665146	Breast Neoplasm	Inhibit immunity	Once activated, p110γ promotes inside-out activation of a single integrin, α4β1, causing myeloid cell invasion into tumors. Pharmacological or genetic blockade of p110γ suppressed inflammation, growth, and metastasis of implanted and spontaneous tumors, revealing an important therapeutic target in oncology.

Summary
Symbol	PIK3R5
Name	phosphoinositide-3-kinase, regulatory subunit 5
Aliases	P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PIK3R5 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PIK3R5
Name	phosphoinositide-3-kinase, regulatory subunit 5
Aliases	P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PIK3R5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.297	0.327
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.364	0.663
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.251	0.715
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.035	0.944
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.409	0.811
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.605	0.802
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.084	0.857
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.389	0.743
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.288	0.831
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.472	0.141
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.976	0.191
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.068	0.709

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PIK3R5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	5.9	1.2	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	6.8	-6.8	0.32
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	14.3	-14.3	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	5.1	-5.1	0.549
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	0	14.3	0.238
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	0	15.4	0.482
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	3.7	-3.7	0.415
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	7.7	-7.7	0.371
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	15.4	-15.4	0.482
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	16.7	-16.7	1

Summary
Symbol	PIK3R5
Name	phosphoinositide-3-kinase, regulatory subunit 5
Aliases	P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PIK3R5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PIK3R5
Name	phosphoinositide-3-kinase, regulatory subunit 5
Aliases	P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PIK3R5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PIK3R5. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PIK3R5
Name	phosphoinositide-3-kinase, regulatory subunit 5
Aliases	P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PIK3R5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PIK3R5
Name	phosphoinositide-3-kinase, regulatory subunit 5
Aliases	P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PIK3R5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PIK3R5
Name	phosphoinositide-3-kinase, regulatory subunit 5
Aliases	P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PIK3R5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PIK3R5
Name	phosphoinositide-3-kinase, regulatory subunit 5
Aliases	P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PIK3R5 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse PIK3R5